Watch Angptl3 Videos

Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies | JACC | ACC.25

Mechanism of Action for ANGPTL3 Inhibitors in HoFH

Inactivation of ANGPTL3 and Cardiovascular Disease

Unlocking the Potential of ANGPTL3 in Dyslipidemia

Lipid Management in 2019: From Inclisaran to ANGPTL3- Evolution or Revolution? - Dr. Robert Rosenson

🧬 Target ANGPTL3, Tame the Lipids, Transform the Risk

Advances in Dyslipidaemia Treatments Focusing on ApoC3 and ANGPTL3 Inhibitors

Evinacumab: Angiopoietin-like protein 3 (ANGPTL3) inhibitor

Evinacumab: Angiopoietin-like protein 3 (ANGPTL3) inhibitor

Lipid Management in 2019: From Inclisaran to ANGPTL3- Evolution or Revolution? - Dr. Robert Rosenson

Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia

Lipidology - B.S. Lewis

New antisense inhibitor nets impressive reductions in lipids

New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3

genetic and pharmacological inactivation of angptl3 and cardiovascular disease

Patient with HoFH Describes His Diagnostic Journey

46. Apo B and Lipoproteins; Genzyme

Treatment Options for HoFH

Unmet Needs in Familial Hypercholesterolemia Management Today

AHA 2020: Evinacumab safety and efficacy in HoFH